Superluminal Medicines raises $60M Series B to launch Phase 1 trial of genetic obesity therapy

Superluminal Medicines, a Boston‑based biotech, announced it has closed a $60 million Series B financing round. The capital will fund the company’s first‑in‑human study of its genetic obesity candidate.

The funding is earmarked for a Phase 1 clinical trial targeting the MC4R pathway, a mechanism shared by other obesity programs such as Rhythm Pharmaceuticals. The trial will assess safety and early signals of efficacy.

By securing this round, Superluminal joins a growing cohort of companies pursuing MC4R‑focused therapies, underscoring continued investor interest in novel obesity treatments.

The raise positions the company to advance its program toward later‑stage development, potentially adding another option to the expanding obesity drug pipeline.